![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Gilead’s Descovy Earns FDA Approval
Gilead’s Descovy Earns FDA Approval
The FDA has approved Gilead Sciences’ combination therapy Descovy for the treatment of HIV-1 infection in adults and pediatric patients.
Indicated for use with other antiretroviral agents in patients 12 and older, the drug is a combination of emtricitabine and tenofovir alafenamide F/TAF. Descovy earned a positive recommendation from the European Medicines Agency in February.
Descovy carries a boxed warning on the risks of lactic acidosis/severe hepatomegaly with steatosis and post-treatment acute exacerbation of hepatitis B.
Upcoming Events
-
21Oct